Can ulcerative colitis patients in remission ditch their daily pill?
NCT ID NCT07718529
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial asks whether adults with ulcerative colitis who are in deep remission can safely stop taking their JAK inhibitor medication (tofacitinib, upadacitinib, or filgotinib) instead of continuing daily maintenance therapy. Half of the 224 participants will stop treatment and be monitored for up to two years, while the other half continues as usual. The goal is to compare safety, effectiveness, and patient satisfaction between the two approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stopping JAK inhibitor treatment (tofacitinib, upadacitinib, or filgotinib)
- What this could lead to
- If successful, this could show that some patients with ulcerative colitis can safely stop their medication without relapse, reducing long-term drug exposure and side effects.
- What could go wrong
- This is a relatively small, open-label trial, and stopping treatment may lead to disease flares. Results may not apply to all patients or other JAK inhibitors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HM hopital Nord
Marseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHRU Besançon
Besançon, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHRU Nancy
Nancy, France
Contact
Contact Email: •••••@•••••
-
CHU Amiens-Picardie
Amiens, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Bordeaux
Bordeaux, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Clermont Ferrand
Clermont-Ferrand, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Montpellier
Montpellier, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Nantes
Nantes, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Nice
Nice, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Nîmes
Nîmes, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Rouen
Rouen, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU St Etienne
Saint-Etienne, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Toulouse
Toulouse, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier d'Avignon
Avignon, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chits Toulon
Toulon, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Lille
Lille, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Rennes
Rennes, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HCL
Lyon, France
-
Hôpital Beaujon
Paris, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Bicêtre
Paris, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Henri-Mondor
Paris, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut des MICI
Paris, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••